Immunovant Inc (IMVT) Company Profile & Statistics

Immunovant Inc
IMVT
(Nasdaq - US)
Open
26.05
-0.58 (-2.18%)
in:usd•As of: Nov 18, 2024 12:32 UTC -5
Open
26.62
High
26.99
Low
25.91

About Immunovant Inc

CEO

Peter Salzmann

Headquarters

320 west 37th street

new york, ny 10018, united states

Auditor

Ernst & Young LLP

Employees

207

Share Holders

Website

www.immunovant.com

Industry

biotechnology

Sector

health technology

Company Overview

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.

Immunovant Inc Statistics

Valuation Measures

Market Capitalization ²	3.82B
Enterprise Value	3.35B
Enterprise Value/EBITDA (ttm)	-9.51
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	8.68
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-56.40%
Return on Invested Capital (ttm)	-60.06%
Return on Assets (ttm)	-52.03%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-352.33M
Net Income Avi to Common (ttm)	-323.01M
Diluted EPS (ttm)	-2.22

Share Statistics

Beta (5Y Monthly)	0.66
52-Week Change	-22.93%
S&P500 52-Week Change	29.63%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	146.78M
Dividend Yield	0.00%
Float ⁴	138.13M
% Held by Insiders	5.90%
% Held by Institutions	47.08%

Balance Sheet

Total Cash (mrq)	472.94M
Total Cash Per Share (mrq)	3.22
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	7.61%
Quick Ratio (mrq)	7.61%
Book Value Per Share (mrq)	3.06

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.13
Free Cash Flow (ytd)	-165.22M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Immunovant Inc

Trade With A Regulated Broker